Leydig Cell Tumor disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LYD001 MIFTS: 45	Leydig Cell Tumor Categories: Cancer diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Leydig Cell Tumor

MalaCards integrated aliases for Leydig Cell Tumor:

Name: Leydig Cell Tumor ¹¹ ⁵³ ⁴³ ¹⁴ ¹⁶ ⁷¹

Leydig Cell Tumor, Benign ⁷¹

Leydig Cell Neoplasm ¹¹

Tumor, Leydig Cell ³⁸

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:2696

MeSH ⁴³ D007984

NCIt ⁴⁹ C3188 C4213

SNOMED-CT ⁶⁸ 45002009 77870005

EFO ¹⁶ EFO_1000321

UMLS ⁷¹ C0023601 C0334409 C0334410

Sources

Summaries for Leydig Cell Tumor

Disease Ontology: ¹¹ A sex cord-gonadal stromal tumor that secretes testosterone characterized by excessive proliferation of Leydig cells located in ovary or testicle.

MalaCards based summary: Leydig Cell Tumor, also known as leydig cell tumor, benign, is related to sertoli-leydig cell tumor and gynecomastia. An important gene associated with Leydig Cell Tumor is CALB2 (Calbindin 2), and among its related pathways/superpathways are Metabolism of steroids and Glucose / Energy Metabolism. The drugs Bevacizumab and Nivolumab have been mentioned in the context of this disorder. Affiliated tissues include ovary, testis and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

Sources

Related Diseases for Leydig Cell Tumor

Diseases related to Leydig Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 416)

#	Related Disease	Score	Top Affiliating Genes
1	sertoli-leydig cell tumor	32.3	SYP INSL3 INHA HSD3BP4 CYP17A1 CALB2
2	gynecomastia	31.1	PRL INHA GNRH1 ESR1 CYP19A1
3	precocious puberty	30.9	LHCGR GNRH1 CYP21A2
4	alopecia, androgenetic, 1	30.8	CYP21A2 CYP19A1
5	androgen insensitivity syndrome	30.7	NR5A1 INSL3 CYP17A1
6	endodermal sinus tumor	30.7	KIT INHA AFP
7	testicular cancer	30.6	TP53 KIT INSL3 GNRH1 ESR1 CALB2
8	appendix adenocarcinoma	30.6	TP53 SYP
9	estrogen excess	30.6	PRL GNRH1 ESR1 CYP19A1
10	adrenogenital syndrome	30.6	SYP INHA CYP21A2
11	hydrocele	30.5	ESR1 CALB2 AFP
12	leiomyoma, uterine	30.5	GNRH1 ESR1 CYP19A1
13	precocious puberty, male-limited	30.4	LHCGR GNRH1 CYP21A2 CYP19A1
14	rete testis adenocarcinoma	30.4	CALB2 AFP
15	endometrial hyperplasia	30.4	TP53 ESR1 CYP19A1 CYP17A1
16	acne	30.4	PRL CYP21A2 CYP19A1 CYP17A1
17	germ cell cancer	30.4	TP53 KIT AFP
18	mixed germ cell-sex cord neoplasm	30.3	KIT CALB2
19	blastoma	30.3	TP53 SYP KIT AFP
20	adrenal adenoma	30.2	CYP21A2 CYP17A1 CYP11A1
21	cystadenoma	30.2	SYP KIT INHA CALB2 AFP
22	seminoma	30.2	TP53 KIT INHA ESR1 AFP
23	amenorrhea	30.1	PRL NR5A1 LHCGR GNRH1 CYP19A1 CYP17A1
24	adenomyosis	30.1	TP53 ESR1 CYP19A1
25	serous cystadenocarcinoma	30.1	TP53 ESR1 CALB2
26	cystadenofibroma	30.1	TP53 CALB2 AFP
27	peutz-jeghers syndrome	30.1	TP53 INHA CYP19A1
28	adenoma	30.0	TP53 SYP PRL LHCGR
29	mature teratoma	30.0	TP53 SYP KIT AFP
30	varicocele	30.0	TP53 PRL GNRH1 ESR1
31	azoospermia	30.0	PRL NR5A1 KIT INSL3 GNRH1 ESR1
32	sertoli cell tumor	30.0	SYP NR5A1 INHA CYP19A1 CALB2 AFP
33	adrenal rest tumor	30.0	INSL3 CYP21A2 CYP11A1
34	hyperprolactinemia	30.0	PTHLH PRL GNRH1
35	oligospermia	30.0	PRL KIT GNRH1
36	teratoma	30.0	TP53 SYP KIT ESR1 CALB2 AFP
37	embryonal carcinoma	29.9	TP53 NR5A1 KIT AFP
38	hypogonadism	29.9	PRL LHCGR GNRH1 CYP19A1
39	cystic teratoma	29.9	TP53 SYP CALB2 AFP
40	benign teratoma	29.9	TP53 SYP CALB2 AFP
41	male infertility	29.9	KIT INSL3 INHA GNRH1 ESR1 CYP21A2
42	complete androgen insensitivity syndrome	29.9	NR5A1 LHCGR INSL3 CYP19A1 CYP17A1
43	ovarian cyst	29.8	PRL GNRH1 ESR1 CYP19A1 AFP
44	gastrointestinal stromal tumor	29.8	TP53 SYP KIT ESR1
45	leiomyoma	29.7	TP53 KIT GNRH1 ESR1 CYP19A1 CYP17A1
46	hyperandrogenism	29.6	PRL INSL3 HSD3BP4 GNRH1 CYP21A2 CYP19A1
47	inguinal hernia	29.6	NR5A1 KIT INSL3 GNRH1 CALB2 AFP
48	endometrial cancer	29.5	TP53 KIT INHA GNRH1 ESR1 CYP19A1
49	myoma	29.5	TP53 PRL KIT GNRH1 ESR1 CYP19A1
50	anovulation	29.2	PRL LHCGR GNRH1 CYP21A2 CYP19A1 CYP17A1

Graphical network of the top 20 diseases related to Leydig Cell Tumor:

Sources

Symptoms & Phenotypes for Leydig Cell Tumor

GenomeRNAi Phenotypes related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

²⁵ (show all 29)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-100	9.88	CYP11A1 CYP21A2
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-102	9.88	NR5A1
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-105	9.88	CYP21A2
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-11	9.88	CYP11A1
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-12	9.88	TP53
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.88	CYP11A1 TP53
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-132	9.88	NR5A1 TP53
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-139	9.88	CYP21A2
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-145	9.88	CYP21A2
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	9.88	CYP21A2
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-166	9.88	CYP11A1
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-169	9.88	TP53
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-173	9.88	NR5A1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-184	9.88	CYP11A1 CYP21A2 NR5A1 TP53
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-185	9.88	CYP21A2
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-19	9.88	TP53
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	9.88	TP53
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-20	9.88	TP53
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-202	9.88	NR5A1
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-203	9.88	CYP21A2
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-206	9.88	CYP21A2
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-208	9.88	CYP21A2
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	9.88	CYP21A2
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-35	9.88	TP53
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-39	9.88	TP53
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	9.88	CYP11A1 NR5A1
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-62	9.88	TP53
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.88	CYP21A2
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-8	9.88	CYP21A2

MGI Mouse Phenotypes related to Leydig Cell Tumor:

⁴⁵ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.25	AFP CYP11A1 CYP17A1 CYP19A1 ESR1 GNRH1
2	nervous system	MP:0003631	10.23	CALB2 CYP11A1 CYP19A1 ESR1 GNRH1 KIT
3	normal	MP:0002873	10.22	CALB2 CYP11A1 CYP19A1 ESR1 GNRH1 INHA
4	growth/size/body region	MP:0005378	10.18	CYP11A1 CYP17A1 CYP19A1 CYP21A2 ESR1 GNRH1
5	liver/biliary system	MP:0005370	10.17	AFP CYP11A1 CYP19A1 ESR1 GNRH1 INHA
6	endocrine/exocrine gland	MP:0005379	10.17	AFP CYP11A1 CYP19A1 ESR1 GNRH1 INHA
7	neoplasm	MP:0002006	10.1	AFP ESR1 GNRH1 INHA KIT PRL
8	behavior/neurological	MP:0005386	10.03	AFP CALB2 CYP11A1 CYP17A1 CYP19A1 CYP21A2
9	digestive/alimentary	MP:0005381	9.86	CYP19A1 ESR1 GNRH1 INHA KIT LHCGR
10	reproductive system	MP:0005389	9.83	AFP CYP11A1 CYP17A1 CYP19A1 ESR1 GNRH1
11	skeleton	MP:0005390	9.32	CYP11A1 CYP17A1 CYP19A1 ESR1 GNRH1 INHA

Sources

Drugs & Therapeutics for Leydig Cell Tumor

Drugs for Leydig Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Nivolumab

Approved

Phase 2

946414-94-4

Ipilimumab

Approved

Phase 2

477202-00-9

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Bleomycin

Approved, Investigational

Phase 2

9041-93-4, 11056-06-7

5360373

Etoposide

Approved

Phase 2

33419-42-0

36462

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Immunoglobulins, Intravenous

Phase 2

Immunoglobulin G

Phase 2

Angiogenesis Inhibitors

Phase 2

Immunologic Factors

Phase 2

Endothelial Growth Factors

Phase 2

Mitogens

Phase 2

Immunoglobulins

Phase 2

Antibodies, Monoclonal

Phase 2

Antibodies

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Immune Checkpoint Inhibitors

Phase 2

Anti-Bacterial Agents

Phase 2

Albumin-Bound Paclitaxel

Phase 2

Etoposide phosphate

Phase 2

16760419

Antimitotic Agents

Phase 2

Tubulin Modulators

Phase 2

Antibiotics, Antitubercular

Phase 2

Gemcitabine

Approved

Phase 1

95058-81-4, 122111-03-9

60750

Antiviral Agents

Phase 1

Anti-Infective Agents

Phase 1

Antimetabolites

Phase 1

Immunosuppressive Agents

Phase 1

Cyclophosphamide

Approved, Investigational

50-18-0, 6055-19-2

2907

Vincristine

Approved, Investigational

2068-78-2, 57-22-7

5978

Dactinomycin

Approved, Investigational

50-76-0

2019 457193

Ifosfamide

Approved

3778-73-2

3690

Doxorubicin

Approved, Investigational

23214-92-8

31703

Palifosfamide

Investigational

31645-39-3

100427

Liposomal doxorubicin

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary	Completed	NCT00748657	Phase 2
2	Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy	Completed	NCT00006227	Phase 2	Paclitaxel
3	A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)	Recruiting	NCT03866382	Phase 2	Cabozantinib S-malate
4	A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary	Active, not recruiting	NCT01042522	Phase 2	Carboplatin;Cisplatin;Etoposide Phosphate;Paclitaxel
5	A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer	Completed	NCT01652794	Phase 1	carboplatin;gemcitabine hydrochloride
6	DICER1 Mutations and miRNA in Ovarian and Testicular Sex Cord Stromal Tumors of Childhood	Completed	NCT01572467
7	A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence	Completed	NCT01764789
8	International Pleuropulmonary Blastoma/DICER1 Registry (for PPB, DICER1 and Associated Conditions)	Recruiting	NCT03382158
9	DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study	Recruiting	NCT01247597
10	Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome	Active, not recruiting	NCT00565903

Search NIH Clinical Center for Leydig Cell Tumor

Cochrane evidence based reviews: leydig cell tumor

Sources

Genetic Tests for Leydig Cell Tumor

Sources

Anatomical Context for Leydig Cell Tumor

Organs/tissues related to Leydig Cell Tumor:

FMA: Ovary

MalaCards : Ovary, Testis, Breast, Endothelial, Testes, Cervix, Skeletal Muscle

Sources

Publications for Leydig Cell Tumor

Articles related to Leydig Cell Tumor:

(show top 50) (show all 1040)

#	Title	Authors	PMID	Year
1	Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells. ⁵³ ⁶²	Sirianni R...Pezzi V	19679653	2009
2	Leydig cell tumor and malignant lymphoma in a patient with nonclassical 21-hydroxylase deficiency. ⁵³ ⁶²	Inaba H...Hashizume K	19367056	2009
3	Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor. ⁵³ ⁶²	Carpino A...Ando S	17656605	2007
4	Possible mechanism for testicular focal necrosis induced by hCG in rats. ⁵³ ⁶²	Chatani F	17077584	2006
5	Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. ⁵³ ⁶²	Basciani S...Gnessi L	15753388	2005
6	Ribonucleic acid expression of the CLA-1 gene, a human homolog to mouse high density lipoprotein receptor SR-BI, in human adrenal tumors and cultured adrenal cells. ⁵³ ⁶²	Liu J...Kahri AI	9253328	1997
7	Occurrence of FSH, inhibin and other hypothalamic-pituitary-intestinal hormones in normal fertility, subfertility, and tumors of human testes. ⁵³ ⁶²	Mehta MK...Sheth AR	7749434	1995
8	Regulation of parathyroid hormone-related peptide production in vitro by the rat hypercalcemic Leydig cell tumor H-500. ⁵³ ⁶²	Liu B...Rabbani SA	8462465	1993
9	Extraadrenal expression of steroid 21-hydroxylase and 11 beta-hydroxylase by a benign testicular Leydig cell tumor. ⁵³ ⁶²	Namiki M...Sonoda T	1751389	1991
10	Leydig cell tumor estrogen secretion: suppression by a gonadotropin releasing hormone agonist. ⁵³ ⁶²	Valensi P...Sebaoun J	1940064	1991
11	Measurement of circulating parathyroid hormone-related protein in rats with humoral hypercalcemia of malignancy using a two-site immunoradiometric assay. ⁵³ ⁶²	Gaich G...Burtis WJ	2387260	1990
12	The structure of cDNA clones encoding the aromatase P-450 isolated from a rat Leydig cell tumor line demonstrates differential processing of aromatase mRNA in rat ovary and a neoplastic cell line. ⁵³ ⁶²	Lephart ED...McPhaul MJ	2340950	1990
13	Histidine decarboxylase inhibitors: a novel therapeutic option for the treatment of leydigioma. ⁶²	Abiuso AMB...Mondillo C	36069766	2022
14	11-Oxygenated androgens are not secreted by the human ovary: in-vivo data from four different cases of hyperandrogenism. ⁶²	Auer MK...Reisch N	36239921	2022
15	Embryonal Rhabdomyosarcoma of the Uterine Cervix: A Clinicopathologic Study of 94 Cases Emphasizing Issues in Differential Diagnosis Staging, and Prognostic Factors. ⁶²	Devins KM...Oliva E	35941719	2022
16	DICER1 mutation in recurrent ovarian Sertoli-Leydig cell tumor: a case report. ⁶²	Liu S...Agrawal A	36402443	2022
17	Pleuropulmonary blastoma (PPB) and other DICER1-associated high-grade malignancies are morphologically, genetically and epigenetically related - A comparative study of 4 PPBs and 6 sarcomas. ⁶²	Hiemcke-Jiwa LS...Flucke U	35779311	2022
18	Precocious Puberty in a Boy With Bilateral Leydig Cell Tumors due to a Somatic Gain-of-Function LHCGR Variant. ⁶²	Flippo C...Dauber A	36111273	2022
19	Is testis sparing surgery safe in patients with incidental small testicular lesions referring to a fertility center? A retrospective analysis reporting factors correlated to malignancy and long-term oncological outcomes. ⁶²	Gobbo A...Levi Setti P	36075820	2022
20	Ovarian Sertoli-Leydig cell tumor: A case report. ⁶²	Liu G...Ye J	36064481	2022
21	Exogenous cholesterol acquisition signaling in LH-responsive MA-10 Leydig cells and in adult mice. ⁶²	Koganti PP...Selvaraj V	35900012	2022
22	DICER1-associated Tumors in the Female Genital Tract: Molecular Basis, Clinicopathologic Features, and Differential Diagnosis. ⁶²	Han LM...Folkins AK	35778792	2022
23	First Evidence of the Expression and Localization of Prothymosin α in Human Testis and Its Involvement in Testicular Cancers. ⁶²	Venditti M...Minucci S	36139050	2022
24	DICER1-Altered Extraovarian Moderately Differentiated Sertoli-Leydig Cell Tumor: Report of a Rare Case. ⁶²	Lau JCC...Liu APY	36044308	2022
25	An Unusual Enteric Yolk Sac Tumor: First Report of an Ovarian Germ Cell Tumor Associated With a Germline Pathogenic Variant in DICER1. ⁶²	McCluggage WG...Foulkes WD	34380971	2022
26	Testicular Lesions in Infertile Men. ⁶²	Dupeux M...Ferlicot S	34935941	2022
27	Collision Tumor of the Ovary Involving Sertoli-Leydig Cell Tumor and High-Grade Serous Carcinoma-Report of the First Case. ⁶²	Omo-Ogboi AC...Tandon N	35838626	2022
28	Precocious puberty related to Leydig cell testicular tumor: the diagnostic imaging keys. ⁶²	Grand T...Rocher L	35550623	2022
29	Anastomosing Hemangioma of the Ovary With Leydig Cell Hyperplasia: A Clinicopathologic Study of 12 Cases. ⁶²	McHenry A...Buza N	35512214	2022
30	Bilateral congenital cryptorchidism and unilateral Leydig cell tumor in an adult presenting with gynecomastia and primary infertility: A case report. ⁶²	Samar MR...Shahzadi M	35303605	2022
31	Yolk Sac Tumor of the Ovary: A Report of 150 Cases and Review of the Literature. ⁶²	Young RH...Stall JN	34469331	2022
32	Transcriptomic analysis of MA-10 tumor Leydig cells treated with adipose derived hormones adiponectin and resistin. ⁶²	Nguyen HT...Martin LJ	34929619	2022
33	Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and Y chromosomal constitution with different genetic etiologies. ⁶²	Lu L...Wang X	35935368	2022
34	Complete androgen insensitivity syndrome - rare case of malignancy of dysgenetic gonads. ⁶²	Gamcova Viktoria...Hudecek Robert	35896396	2022
35	A Matter of Time: Delayed Presentation and Rapid Progression from Gonadotropin-Independent to Gonadotropin-Dependent Precocious Puberty following Successful Treatment for a Leydig Cell Tumor. ⁶²	Naotunna CR...Atapattu N	35036017	2022
36	Bilateral testicular Leydig cell hyperplasia presented incidentally: A case report. ⁶²	Al-Zubi M...Qasim TS	34968979	2022
37	15-Year-Old Patient with an Unusual Alpha-Fetoprotein-Producing Sertoli-Leydig Cell Tumor of Ovary. ⁶²	Serife K...Vanden Houte K	35450124	2022
38	Testicular cancer among Saudi adults: Hands on a nationwide Cancer Registry over 10 years. ⁶²	Noureldin YA...Alkhayal A	36353476	2022
39	DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma. ⁶²	Gonzalez IA...Dehner LP	34599283	2022
40	Leydig Cell Tumor-Induced Gonadotropin-Independent Precocious Puberty Progressing to Gonadotropin-Dependent Precocious Puberty Post Orchiectomy: Out of the Frying Pan Into the Fire. ⁶²	Singhania P...Chowdhury S	35165615	2022
41	cAMP-specific phosphodiesterase 8A and 8B isoforms are differentially expressed in human testis and Leydig cell tumor. ⁶²	Campolo F...Barbagallo F	36277728	2022
42	Testis-sparing surgery in children with testicular tumors: A systematic review and meta-analysis. ⁶²	Miao X...Lv M	33893031	2021
43	Clinical heterogeneity and reduced penetrance in DICER1 syndrome: a report of three families. ⁶²	Azzollini J...Manoukian S	34761719	2021
44	Effect of androgens on Sertoli cell maturation in human testis from birth to puberty. ⁶²	Lapoirie M...Plotton I	34906089	2021
45	Thoracic Sertoli-Leydig cell tumor: An alternative type of pleuropulmonary blastoma associated with DICER1 variation. ⁶²	Terry W...Schultz KAP	34398502	2021
46	Krukenberg Tumor of Ovary During Pregnancy: Learning From A Mistake. ⁶²	Jha S...Jena SK	33252404	2021
47	A case of neoplastic synchronism in a dog. ⁶²	Rifici C...Mazzullo G	34411998	2021
48	Postmenopausal women with hyperandrogenemia: Three case reports. ⁶²	Zhu XD...Jiang TA	34754857	2021
49	Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features. ⁶²	Rizzo NM...Acosta AM	34103665	2021
50	Primary Biphasic Hepatic Sarcoma in DICER1 Syndrome. ⁶²	See SC...Arva NC	33872107	2021

Sources

Genes for Leydig Cell Tumor

Genes related to Leydig Cell Tumor (0 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	CALB2	Calbindin 2	Protein Coding	22.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14608532
2	C19orf53	Chromosome 19 Open Reading Frame 53	Protein Coding	22.05	DISEASES inferred ¹⁴ GeneCards inferred via : Gene name Proteins (show sections)
3	CYP21A2	Cytochrome P450 Family 21 Subfamily A Member 2	Protein Coding	20.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1751389 19367056
4	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	19.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	20026603 10623684 17656605 (more) 1965908 19679653 2340950 9365213
5	CYP17A1	Cytochrome P450 Family 17 Subfamily A Member 1	Protein Coding	19.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1323057 15761033 8994191
6	PTHLH	Parathyroid Hormone Like Hormone	Protein Coding	17.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8462465 1338636 2387260
7	STAR	Steroidogenic Acute Regulatory Protein	Protein Coding	16.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10098511 15814901 9348220 (more) 8961254 11823449 14660163 16469751 9582502 10418988 11911946 12647776 16901926 12810543 15498831 12943700 11545297 8969911
8	LHCGR	Luteinizing Hormone/Choriogonadotropin Receptor	Protein Coding	15.5	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11823449 12933660 11861529 (more) 12150333 12408104 10446904
9	GNRH1	Gonadotropin Releasing Hormone 1	Protein Coding	15.3	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1940064
10	INSL3	Insulin Like 3	Protein Coding	14.41	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	AFP	Alpha Fetoprotein	Protein Coding	14.26	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	CYP11A1	Cytochrome P450 Family 11 Subfamily A Member 1	Protein Coding	14.22	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10418988
13	HSD3BP4	Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta, Pseudogene 4	Pseudogene	14.19	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8243310
14	ESR1	Estrogen Receptor 1	Protein Coding	13.46	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	SYP	Synaptophysin	Protein Coding	13.26	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	NR5A1	Nuclear Receptor Subfamily 5 Group A Member 1	Protein Coding	13.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	20026603 8395654 19679653
17	INHA	Inhibin Subunit Alpha	Protein Coding	13.16	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	PRL	Prolactin	Protein Coding	13.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	12.5	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	TP53	Tumor Protein P53	Protein Coding	12.4	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Leydig Cell Tumor

Sources

Expression for Leydig Cell Tumor

Search GEO for disease gene expression data for Leydig Cell Tumor.

Sources

Pathways for Leydig Cell Tumor

Pathways related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Metabolism of steroids ⁶⁶ Show member pathways Activation of gene expression by SREBF (SREBP) ⁶⁶ allopregnanolone biosynthesis ⁶¹ androgen biosynthesis ⁶¹ Cholesterol synthesis disorders ⁷⁴ Defective CYP17A1 causes AH5 ⁶⁶ Regulation of cholesterol biosynthesis by SREBP (SREBF) ⁶⁶ Sterol regulatory element-binding proteins (SREBP) signaling ⁷⁴ Vitamin D (calciferol) metabolism ⁶⁶	12.33	STAR CYP21A2 CYP19A1 CYP17A1 CYP11A1
2	Glucose / Energy Metabolism ³	12.27	STAR CYP19A1 CYP17A1 CYP11A1
3	Corticotropin-releasing hormone signaling pathway ⁷⁴	11.59	STAR CYP21A2 CYP11A1
4	Glucocorticoid receptor regulatory network ⁶¹	11.47	TP53 PRL AFP
5	Ovarian infertility ⁷⁴	11.01	NR5A1 LHCGR INHA CYP19A1
6	Metabolism of steroid hormones ⁶⁶ Show member pathways Androgen biosynthesis ⁶⁶ Defective CYP11A1 causes AICSR ⁶⁶ Defective CYP11B1 causes AH4 ⁶⁶ Defective CYP21A2 causes AH3 ⁶⁶ Electron transport from NADPH to Ferredoxin ⁶⁶ Estrogen biosynthesis ⁶⁶ Glucocorticoid and Mineralcorticoid Metabolism ⁷⁴ Glucocorticoid biosynthesis ⁶⁶ Mineralocorticoid biosynthesis ⁶⁶ Pregnenolone biosynthesis ⁶⁶	11.01	STAR CYP21A2 CYP19A1 CYP17A1 CYP11A1
7	Metabolic disorders of biological oxidation enzymes ⁶⁶	10.79	CYP21A2 CYP19A1 CYP17A1 CYP11A1
8	Hormone ligand-binding receptors ⁶⁶	10.51	LHCGR GNRH1
9	Alternative pathway of fetal androgen synthesis ⁷⁴	10.47	STAR CYP17A1 CYP11A1
10	Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics ⁶⁰	9.92	ESR1 CYP19A1

Sources

GO Terms for Leydig Cell Tumor

Biological processes related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	ovarian follicle development	GO:0001541	9.93	LHCGR KIT INHA
2	sterol metabolic process	GO:0016125	9.85	CYP21A2 CYP19A1 CYP11A1
3	female gonad development	GO:0008585	9.8	NR5A1 LHCGR CYP19A1
4	uterus development	GO:0060065	9.8	LHCGR ESR1 CYP19A1
5	positive regulation of RNA polymerase II transcription preinitiation complex assembly	GO:0045899	9.73	TP53 ESR1
6	male gonad development	GO:0008584	9.73	NR5A1 LHCGR KIT INSL3 INHA ESR1
7	negative regulation of miRNA maturation	GO:1903799	9.65	TP53 ESR1
8	regulation of steroid biosynthetic process	GO:0050810	9.65	LHCGR NR5A1 STAR
9	glucocorticoid biosynthetic process	GO:0006704	9.63	CYP21A2 CYP17A1 CYP11A1
10	steroid biosynthetic process	GO:0006694	9.28	STAR CYP21A2 CYP19A1 CYP17A1 CYP11A1

Molecular functions related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	heme binding	GO:0020037	9.92	CYP21A2 CYP19A1 CYP17A1 CYP11A1
2	iron ion binding	GO:0005506	9.86	CYP21A2 CYP19A1 CYP17A1 CYP11A1
3	monooxygenase activity	GO:0004497	9.46	CYP21A2 CYP19A1 CYP17A1 CYP11A1
4	hormone activity	GO:0005179	9.32	PTHLH PRL INSL3 INHA GNRH1
5	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	GO:0016705	9.26	CYP21A2 CYP19A1 CYP17A1 CYP11A1